TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10211015
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine (40 mg bolus followed by 15 mg h‐1 infusion)
Study: 26571884
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and medication group (acupuncture + 20 mg fluoxetine once daily for 4 weeks)
Study: 26571884
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (20 mg fluoxetine once daily for 4 weeks)
Study: 17146419
Drug: food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: food supplement containing hydrolyzed sea fish cartilage, vitamin C, vitamin E, folic acid, zinc, copper (Captafer)
Study: 17146419
Drug: food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: food supplement
Study: 1582107
Drug: Conventional ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional ibuprofen tablets 600 mg QID (CI)
Study: 1582107
Drug: Sustained-release ibuprofen
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release ibuprofen tablets 1200 mg BID (SRI)
Study: 3973309
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food challenge with suspected food
Study: 27369044
Drug: Bi-weekly emails
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly emails for first 4 weeks and then weekly emails for the next 8 weeks targeting self‐efficacy, social support, goal setting, and benefits/barriers to walking (Dog owners)
Study: 27369044
Drug: Bi-weekly emails
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly emails for first 4 weeks and then weekly emails for the next 8 weeks targeting self‐efficacy, social support, goal setting, and benefits/barriers to walking (Non-dog owners)
Study: 23800154
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q‐Ter for 2 months (Group A)
Study: 21555764
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETR) 200 mg q12h
Study: 21555764
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETR) combined with Lopinavir (LPV)/Ritonavir (RTV) 200/400/100 mg q12h
Study: 21555764
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETR) combined with Darunavir (DRV)/Ritonavir (RTV) 200/600/100 mg q12h
Study: 19327739
Drug: Intraoperative sub-Tenon
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative sub-Tenon injection of triamcinolone acetonide (TA)
Study: 19327739
Drug: No intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intraoperative sub-Tenon injection of triamcinolone acetonide (TA)
Study: 17576909
Drug: Antiviral plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral plus steroid therapy
Study: 9556926
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of antibodies against Trypanosoma cruzi using a commercial ELISA kit
Study: 8052870
Drug: Carboplatin/etoposide chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/etoposide chemotherapy and thoracic irradiation
Study: 8052870
Drug: Cisplatin/etoposide chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/etoposide chemotherapy and thoracic irradiation
Study: 28870191
Drug: Translatory dorsal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Translatory dorsal glide mobilization (TDGM) C0‐C1 technique, adjunct to protocolized physiotherapy treatment
Study: 28870191
Drug: Pressure maintained
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressure maintained suboccipital inhibition technique (PMSIT), adjunct to protocolized physiotherapy treatment
Study: 28870191
Drug: Protocolized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized treatment (Control Group)
Study: 22978325
Drug: Music-movement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-movement therapy (60 minutes, three times per week for 8 weeks)
Study: 22101378
Drug: Oral valganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valganciclovir (VGCV) 900 mg/day
Study: 22101378
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (GCV) 5 mg/kg twice daily
Study: 2941056
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/Codeine 30 mg (medium-dose combination)
Study: 2941056
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ibuprofen/codeine combination
Study: 2941056
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ibuprofen/codeine combination
Study: 24406723
Drug: Intranasal orexin-A
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal orexin-A (435 nmol)
Study: 16282050
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal drug therapy (glucosidorum Tripterygii totorum tablets and Yishen Juanbi Tablets)
Study: 16282050
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine therapy (voltaren extended release tablets, methotrexate, and sulfasalazine)
Study: 2167952
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy at 69.6 Gy
Study: 2167952
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy at 60.0 to 64.8 Gy
Study: 2167952
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy at 69.6 to 74.4 Gy
Study: 2167952
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy at 79.2 Gy
Study: 28628679
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate (IngMeb) gel at concentrations of 0.018% and 0.027%, applied once daily for 2 or 3 days
Study: 26117164
Drug: Implicit emotion
Normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Implicit emotion regulation intervention via psychotherapy (specific dosage and duration not mentioned)
Study: 21616527
Drug: Terutroban (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terutroban (30 mg per day)
Study: 19004549
Drug: Subcutaneous Botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Botulinum toxin type A (BoNT/A) 22.5U
Study: 17530942
Drug: T. terrestris
Approvals — FDA: no, EMA: no, PMDA: no
Description: T. terrestris (450 mg.d(‐1))
Study: 15126543
Drug: Methyltestosterone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyltestosterone (2.5 mg/d) plus esterified estrogens (1.25 mg/d)
Study: 15466635
Drug: Systemic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic heparin treatment throughout the procedure
Study: 7627280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sperm injection)
Study: 6795461
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of vaccine (20 micrograms per dose) at 0, 1 and 6 months
Study: 6795461
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of vaccine (20 micrograms per dose) + 3 ml of HBIG with the first dose
Study: 6795461
Drug: HBIG together
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG together with the first and second doses of vaccine
Study: 31112623
Drug: Vilaprisan 2
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 2 mg
Study: 28064304
Drug: Ophthalmic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic artery branch retrograde intervention with urokinase (400,000 U) and papaverine (30 mg)
Study: 28064304
Drug: Superselective ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superselective ophthalmic artery/selective carotid intervention with urokinase (400,000 U) and papaverine (30 mg)
Study: 26602322
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel in combination prior to CAS
Study: 21119312
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections (intra-articular or subacromial) with local anesthetic
Study: 31061017
Drug: liraglutide placebo
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide placebo 3 mg/day
Study: 26790823
Drug: Clomethiazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomethiazole treatment after 24 hours
Study: 22779218
Drug: Oral-B Indicator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B Indicator manual toothbrush (MT)
Study: 9133695
Drug: Radioiodine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine treatment with a standard activity of 15 mCi (555 MBq) of 131I
Study: 9133695
Drug: Target dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose of 100 Gy
Study: 9133695
Drug: Standard activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard activity (15 mCi) with additional calculation of actual target dose
Study: 3307900
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (2 mg/kg)
Study: 26993629
Drug: Preventive cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive cognitive therapy with gradual, guided discontinuation of SSRIs under medical management (STOP)
Study: 26993629
Drug: Preventive cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive cognitive therapy with gradual, guided discontinuation of SSRIs (STOP)
Study: 25825421
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (40 units into each pectoralis major muscle through 4 serial injections)
Study: 25825421
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl, 4 serial injections)
Study: 23380314
Drug: l-5-hydroxytryptophan (l-5-HTP)
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-5-hydroxytryptophan (l-5-HTP)
Study: 16169344
Drug: Rotational atherectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotational atherectomy (RA) followed by beta-radiation therapy
Study: 16169344
Drug: Cutting balloon
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cutting balloon angioplasty (CBA) followed by beta-radiation therapy
Study: 12848680
Drug: Imagent (perflexane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagent (perflexane lipid microspheres) administered as an IV bolus at 0.125 mg/kg body weight
Study: 15321322
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 2.0 ml hyperbaric 0.5% bupivacaine
Study: 15321322
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia with a local anaesthetic mixture (0.5% bupivacaine plain 10 ml, 2% lignocaine plain 10 ml, 0.1 ml of adrenaline 1 in 1000, and 2 ml of 8.4% sodium bicarbonate)
Study: 1817663
Drug: Cantamega‐2000 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cantamega‐2000 (1 tablet daily at breakfast for 4 weeks)
Study: 1817663
Drug: Polivitaminizant S
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polivitaminizant S (2 tablets daily at breakfast for 4 weeks)
Study: 30663977
Drug: IBI305 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI305 (3 mg/kg)
Study: 30353619
Drug: linaclotide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: linaclotide 0.5 mg
Study: 27737713
Drug: Self-management plan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management plan with a temporary quadrupling of the dose of inhaled corticosteroid (maximum of 14 days)
Study: 27737713
Drug: Self-management plan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management plan without an increase in inhaled corticosteroid
Study: 24588434
Drug: Low-intensity CRRT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity CRRT (25 mL/kg/hour)
Study: 24588434
Drug: High-intensity CRRT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity CRRT (40 mL/kg/hour)
Study: 20090434
Drug: Scheduled dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled dosing of acetaminophen and hydrocodone (167 mg/2.5 mg/5 mL) every 4 hours ATC (Groups B and C)
Study: 20090434
Drug: PRN dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN dosing of acetaminophen and hydrocodone every 4 hours (Group A)
Study: 20090434
Drug: Scheduled dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled dosing of acetaminophen and hydrocodone (167 mg/2.5 mg/5 mL)
Study: 17526976
Drug: Nicorandil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (5 mg tid)
Study: 17526976
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN: 20 mg bid)
Study: 15476906
Drug: Valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 40 mg/d
Study: 11522870
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (12 g/day)
Study: 8156094
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy for 3 years
Study: 3045718
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose gentamicin therapy (n = 39)
Study: 3045718
Drug: Seven day
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven day course of an appropriate antibiotic (n = 30)
Study: 3045718
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose gentamicin therapy
Study: 3045718
Drug: Seven day
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven day course of an appropriate antibiotic
Study: 27662042
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin by jet injection (0.2 units/kg)
Study: 27662042
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart by conventional pen
Study: 24895108
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) 62.5 mcg QD
Study: 24895108
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) 125 mcg QD
Study: 24895108
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) doses ≥62.5 mcg QD
Study: 24895108
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) BID dosing
Study: 24895108
Drug: Umeclidinium (UMEC)
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (UMEC) QD dosing
Study: 23165811
Drug: Normal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal group (hemoglobin concentration 12-15 g/dl), n=42
Study: 23165811
Drug: Anemic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemic group (hemoglobin concentration 7-10 g/dl), n=44
Study: 23165811
Drug: Anemic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemic group (hemoglobin concentration 7-10 g/dl)
Study: 18414916
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg morphine
Study: 10378673
Drug: Constant rate
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant rate infusion of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule A)
Study: 10378673
Drug: Chronotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapy with sinusoidal modulation of HAI FUDR (80 mg/m2/day) and i.v. 5-FU (1200 mg/m2/day) for 5 days every 3 weeks (schedule B)
Study: 10378673
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A (Constant rate infusion)
Study: 1986037
Drug: Thiamin supplementation
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamin supplementation (10 mg daily)
Study: 6688635
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (650 mg)
Study: 6688635
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen elixir (650 mg)
Study: 6688635
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen tablet (650 mg)
Study: 6688635
Drug: Two commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two commercially available tablet formulations (325 mg each)
Study: 27477485
Drug: scFOS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS (5 g d-1) for 4 weeks
Study: 22522141
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg/day with probiotics (Enterococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Bacillus coagulans 50 million spores) at a dose of two capsules three times daily (group 1)
Study: 22522141
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg/day with probiotics (group 1)
Study: 17590511
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg levodopa/50 mg benserazide during endurance exercise
Study: 17590511
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg levodopa/50 mg benserazide during rest
Study: 16304854
Drug: Clopidogrel Lowplat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel Lowplat (drug B) 600 mg (8 tablets) given once
Study: 16304854
Drug: Clopidogrel Plavix
Normalized name: clopidogrel Oral Tablet [Plavix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel Plavix (drug A) 600 mg (8 tablets) given once
Study: 11943134
Drug: Erythromycin 600
Normalized name: erythromycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 600 mg during fasting and 1 g postprandially
Study: 9805101
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g for 5 days, then 3 g daily)
Study: 7714978
Drug: Polyestradiol phosphate
Normalized name: POLYESTRADIOL PHOSPHATE
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyestradiol phosphate plus ethinylestradiol (80 mg polyestradiol phosphate by intramuscular injection every 4 weeks plus 50 micrograms ethinylestradiol 3 times daily)
Study: 7714978
Drug: Estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estramustine phosphate (280 mg 2 times daily)
Study: 7714978
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (surveillance only)
Study: 26945929
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide and albuterol delivered via the Combivent Respimat Soft Mist Inhaler (CVT-R)
Study: 26945929
Drug: Chlorofluorocarbon-propelled Combivent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorofluorocarbon-propelled Combivent metered-dose inhaler (CVT-MDI)
Study: 20649032
Drug: Neutral protamine
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral protamine Hagedorn plus metformin
Study: 18517112
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg kg(‐1)) and Remifentanil (0.1 microg kg(‐1) min(‐1))
Study: 26332701
Drug: Hydrocodone‐acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone‐acetaminophen